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Objectives: Heat shock proteins are overexpressed in many human malignancies. The role of 
heat shock proteins as a therapeutic target in cancer as well as their association with drug 
resistance were widely documented. The aim of this study was to evaluate the concentration of 
IgG class HSP27 and HSP60 antibodies in serum of patients with endometrial and cervical 
cancer, as well as to analyse the variability of concentrations of the examined antibodies 
depending on the cancer stage. 
Results:  In both endometrial and cervical cancer, the serum concentration of IgG anti-HSP27 
antibody was significantly higher than in the healthy control group. The concentration of IgG 
anti-HSP60 antibody in endometrial cancer, cervical cancer and healthy control was similar. 
The median IgG anti-HSP27 antibody serum concentration of endometrial cancer patients was 
not correlated with FIGO-stage. In cervical cancer inverse correlation between concentration 
of this antibody and FIGO stage was observed. 
The median IgG anti-HSP60 antibody concentration in serum of endometrial cancer patients 
was lower in FIGO stage I and II compared to FIGO stage IV and in FIGO stage IA compared 
to FIGO stage IB. Concentrations of examined antibodies correlated positively with each other, 
both in the group of women with cancer and in the group of healthy women. The strongest 
correlations were found in the group of patients with endometrial cancer. 
Conclusions: Concentration of anti-HSP27 antibody could help in detection of cervical and 
endometrial cancer. We need to look for the cut-off point in large cohort studies. Anti-HSP27 
and anti-HSP60 antibodies should be further evaluated for their potential usage as biomarkers 
in cervical and endometrial cancer as they shown some correlation with stage of disease. 









Endometrial cancer is the most common malignancy of the female reproductive organs, 
and approximately one-fifth of patients are diagnosed at an advanced stage [1]. The incidence 
of this cancer is steadily increasing due to rising standards of living in the populations of 
developed countries [2, 3]. Although this neoplasm is most often diagnosed at the first clinical 
stage according to FIGO [4], there is still a search for simple tumour markers that allow the 
diagnosis and identification of women from high-risk groups. The reason being the 
imperfection of the applied diagnostic methods, mainly an endometrial biopsy, which, due to 
technical errors during the procedure or an insufficient amount of material, have a high 
percentage of false negative results [5]. 
 Cervical cancer is the second most common cancer in women [6]. Its occurrence is 
steadily increasing, especially in developing countries [7]. Lack of awareness and insufficient 
care for women’s health are possible reasons for the rising incidence rates in recent years [8]. 
Additionally, the pathogenesis of this cancer is unclear and may be due to recurrent genetic 
changes, microenvironments, lifestyle, smoking, etc. [9]. Various studies have shown that 
persistent HPV infection is a major causative factor in cervical cancer, but only a small 
proportion of patients with HPV infection will eventually progress to cervical cancer. In 
cervical cancer patients, the mode of treatment depends on staging and parametrial infiltration, 
which is a critical factor in determining treatment planning [10]. Etiological studies have shown 
that the occurrence of this cancer is a complicated process that includes many factors, and its 
molecular mechanism has not yet been fully explained. Therefore, there is a need to find an 
indicator that predicts precancerous changes that lead to cancer [7]. 
 Heat shock proteins (HSPs) and the immune response directed against them are 
intensively studied by modern oncologists. They are overexpressed in many human 
malignancies. The heat shock response (HSR) is a basic adaptation of the body to endo- and 
exogenous stress conditions. It results in the synthesis and increased expression of heat shock 
proteins [11, 12], which have a protective effect as they neutralise the effects of cellular stress 
[13]. These proteins protect intracellular proteins from damage leading to their apoptosis [14]. 
On the other hand, a marked and rapid overexpression of most HSPs in response to cellular 
damage is found, with cancer cells having been found to over-stimulate the synthesis of heat 
shock proteins [15]. This may be of fundamental importance in the pathogenesis and 
progression of cancer — the significant role of heat shock proteins as a therapeutic target in 
cancer has been demonstrated [16, 17] but, on the other hand, they are also associated with drug 
resistance in cancer [18]. 
 The endometrium contains many types of heat shock proteins. Among them are HSP27, 
HSP60, HSP65, HSP70 and HSP90. The intensity of expression of HSP proteins is changeable 
during the menstrual cycle – there is an inverse correlation between their activity and the 17-ß-
estradiol concentration in the human endometrium [19]. Additionally, the association and 
affinity of HSP27 with the oestrogen receptor in endometrial cancer cells has been 
demonstrated [20]. Therefore, HSP27 is a protein that may be involved in the pathomechanism 
of the development of endometrial cancer, especially since it is overexpressed in the neoplastic 
endometrium [21]. The role of the HSP27 protein in patients is not completely clear. Some 
authors believe that the presence of increased expression of HSP27 is a favourable prognostic 
factor, others report that this protein is a marker that significantly decreases the prognosis in 
terms of treatment efficacy and the recurrence-free period, while still others believe that HSP27 
expression is only associated with a good prognosis in endometrial adenocarcinomas, and that 
the degree of histological differentiation of the endometrial cancer affects HSP27 protein 
expression – a positive correlation was demonstrated in a well-differentiated cancer [22, 23]. 
 The role of heat shock proteins in cervical cancer has not yet been sufficiently studied 
and some aspects are still under investigation. The effect of several HSPs in patients with 
cervical cancer has been analysed in the literature, especially for the HSP70, 60, and 90 groups 
[24, 25]. However, the results of studies on heat shock proteins in patients with cervical cancer 
are heterogeneous. 
 Although heat shock proteins are promising compounds for the detection, diagnosis and 
treatment of the analysed cancers, they still require further studies and observations. The aim 
of this study was to evaluate the concentration of IgG class antibodies for the heat shock 
proteins HSP27 and HSP60 in the serum of patients with endometrial or cervical cancer, as well 
as to analyse the variability of the concentrations of the tested antibodies depending on the 
clinical stage of the cancer (FIGO classification). 
 
MATERIAL AND METHODS 
 
 The study included 59 women with adenocarcinoma of the endometrium and 36 women 
with cervical cancer. All patients were hospitalised in the Department of Gynaecology, 
Obstetrics and Gynaecology Oncology, Medical University of Silesia. Patients with coexisting 
diseases were excluded from the study. The control group consisted of 54 healthy women 
attending routine gynaecological examinations at the Gynaecological Outpatient Clinic. 
 For both groups, 5 mL of blood for analysis was collected from each patient in the 
morning, on an empty stomach, from the ulnar flexor vein. After collection, the blood was 
centrifuged, and the serum obtained was stored at -70o C until assayed.  
 The research protocol was approved by the Bioethics Commission of the Medical 
University of Silesia, and all patients were informed about the purpose of the study and agreed 
in writing to participate. 
 The concentrations of IgG class antibodies against the tested heat shock proteins were 
determined by an immunoenzymatic assay (ELISA) using commercial assays.  
The obtained results are presented using basic parameters of descriptive statistics. The 
conformity of the distribution of the variables to the normal distribution was checked with the 
Szapiro-Wilk test. Nonparametric Kolmogorov-Smirnov and Mann-Whitney U tests were used 
for comparisons between the groups. The Kruskal-Wallis rank-sum ANOVA test was used to 
examine variability within the endometrial cancer group. The correlation between parameters 
was examined using Spearman’s rank correlation test. A p-value less than 0.05 was considered 





The average age of the patients with endometrial or cervical cancer and the healthy 
women was similar and not statistically different (p > 0.05). Similarly, there was no significant 
difference between the ages of patients in the different stages of cancer (Tab. 1). Table 1 
presents the structure of the group of women with endometrial or cervical cancer depending to 
the clinical stage of the neoplastic process according to FIGO classification. In the case of 
endometrial cancer, both FIGO stages I and II were diagnosed in 21 patients (35.6% each), 
while stage IV was the least frequently found (5 patients, i.e., 8.5% of cases). A slightly 
different tumour progression was observed in the patients with cervical cancer. In this group, 
the most frequent tumour grade was II – almost half of the patients (47.2% of cases). 
 After the assays were performed and the results obtained, the concentrations of the 
tested antibodies in the serum of women with endometrial adenocarcinoma or cervical cancer 
were compared with the concentrations of these antibodies in the serum of the women in the 
control group. The results of these comparisons are presented in Table 2. 
In both endometrial and cervical cancer patients, the concentrations (medians) of IgG 
antibodies to HSP27 (p < 0.01 and p = 0.026 for the Kolmogorov-Smirnov and Mann-Whitney 
U tests, respectively, for endometrial cancer and p = 0.022 and p = 0.041 for the Kolmogorov-
Smirnov and Mann-Whitney U tests, respectively, for cervical cancer) were significantly higher 
than in the control group of healthy women. However, for both cancers, the IgG anti-HSP60 
antibody levels were comparable in both groups (Tab. 2).  
Table 3 presents the concentrations of the tested antibodies (medians) depending on the 
clinical stage of the neoplastic process assessed according to the FIGO classification. 
In the patients with endometrial cancer, anti-HSP60 antibody concentrations in those 
women with FIGO I and FIGO II are significantly lower than in those with FIGO IV (p = 0.019 
and p = 0.024, respectively). There were no differences between the anti-HSP27 antibody levels 
in this group of patients. The results of the cervical cancer patients are slightly different. In this 
group, we observed a decrease in the concentrations of the tested antibodies depending on the 
tumour stage. Significantly higher concentrations of anti-HSP27 were observed in those women 
with FIGO I and FIGO II than in those with FIGO IV (p = 0.0001 and p = 0.003, respectively) 
and higher concentrations of anti-HSP60 in those women with FIGO I and FIGO III than in 
those with FIGO IV (p = 0.023 and p = 0.0011, respectively). Due to the inverse trend of the 
behaviour of the concentrations of the tested antibodies in both diseases, they were not 
compared with each other. 
In patients with endometrial cancer at clinical stage I according to FIGO, the 
concentrations of the tested antibodies were analysed in relation to the depth of tumour 
infiltration. The results of this analysis are presented in Table 4. It turned out that in cases of 
neoplastic infiltration of less than 50 % of the endometrium (FIGO stage IA), the concentration 
of antibodies in the IgG group is lower than in the case of clinical stage IB, where half or more 
of the endometrial thickness is affected by the neoplastic process. The mentioned relationship 
concerns both anti-HSP27 and anti-HSP60 antibodies. 
An assessment of the possible correlations of the concentrations of the tested antibodies 
in ill and healthy women with their age and an assessment of the possible correlations between 
the concentrations of antibodies against particular HSPs in the examined groups were also 
performed. The concentrations of anti-HSP27 and anti-HSP60 antibodies did not correlate with 
the age of the women in any of the examined groups. The concentrations of the tested antibodies 
correlated positively with each other, both in those women with cancer and in the healthy group. 
The strongest correlations were found in the group of patients with endometrial cancer. The 
results are shown in Table 5. 
 
DISCUSSION 
In our study of endometrial cancer, the largest group was for patients with an earlier 
tumour stage according to FIGO (stages I and II). Similar results were presented by Hou et al. 
[26], with 73.9% of patients at stages I and II, and the rest of the group studied in his report 
(stages III and IV) accounting for 26.1%, as well as by Helpman et al. [27], who in their large 
study of more than 20,000 patients with endometrial cancer describe that 73% of tumours were 
confined to the uterus, so the stage was I or II. A slightly different cross-section of tumour 
progression was obtained by Van Walree et al. [28], who report that FIGO stage I patients 
comprise as many as 88% of the study participants, while stage II patients comprise only 3%. 
This difference is probably due to the broad exclusion criteria used in the Van Walree et al., 
study; some patients with progressive disease were excluded from participation. In our study, 
we also obtained a similar cross section of cancer stage for patients with endometrial cancer, as 
have other authors [8]. 
The primary objective of this study was to evaluate the concentrations of IgG class 
antibodies against selected heat shock proteins in the serum of women with endometrial or 
cervical cancer. 
The study in endometrial cancer patients focused on type 1 endometrial cancer due to it 
affecting 80% of patients. In our study, IgG anti-HSP27 antibody levels were higher in the study 
group compared to the healthy women. The results are consistent with the reports of other 
authors, as overexpression of anti-HSP27 antibodies was detected in cases of endometrial 
cancer [29]. Heat shock proteins protect against the effect of exogenous stress, which translates 
into their higher concentration in endometrial cancer patients (and other cancers) [30]. The 
results of the concentrations of these proteins in women with epithelial endometrial cancer, 
different to ours, were presented by Boeddeker et al. [31]. In their study, before apoptosis 
induction, HSP60 concentrations were lower in women with endometrial cancer in comparison 
to healthy controls, and HSP27 concentrations did not differ between the groups. After the 
induction of apoptosis, the concentrations of the tested antibodies were lower in women with 
endometrial cancer. The results of Boeddeker et al. can be explained by the fact that the HSP27 
protein is considered an inhibitory factor for apoptosis, which has also been mentioned by other 
authors [30, 32, 33]. 
In their studies, Ramezani along with Aghakhani et al., [30] showed higher anti-HSP27 
antibody levels in women exposed to HPV than in the control group. This is consistent with our 
results and demonstrates that HSP27 is a biomarker for HPV infection as well as a therapeutic 
target for cancer [30, 34]. 
In our study, we obtained a correlation of a clear increase in antibody concentrations 
with the FIGO stage of endometrial cancer. A particularly pronounced increase was noted in 
the case of anti-HSP60. Similar conclusions have been reached by other studies. It appears that 
extracellular HSP proteins and HSP-rich extracellular vesicles can promote cancer progression. 
Moreover, they enhance migration, invasion, heterogeneity, metastasis, and drug resistance in 
cancer cells, but most importantly they promote tumour angiogenesis [35, 36]. The cited facts 
clearly explain the increase in the concentrations of HSP proteins and, consequently, the 
antibodies tested with the stage of this cancer. In the case of cervical cancer, we obtained results 
suggesting a decrease in the concentration of anti-HSP27 antibodies with tumour progression. 
This is probably due to the inhibitory effect of lambertian acid on HSP27 phosphorylation and, 
consequently, to the impaired binding of HSP27 to the factors promoting its synthesis, as 
described by Lee et al. [37]. It should also be remembered that cervical cancer develops slowly 
– therefore we found the highest concentration of anti-HSP27 antibodies in FIGO stage I, as in 
the case of a slow-growing cancer an enhanced autoimmune response may be expected in the 
early stages of its development. We believe that the enhanced nature of the immune response 
against HSP27 in patients with cervical cancer may indicate an increased expression of this 
protein, especially in the early stages of the disease and suggests its involvement in the 
oncogenesis process of this cancer. 
We did not get a clear answer why the behaviour of anti-HSP60 antibodies in women 
with cervical cancer depends on the stage — the highest levels were found in the FIGO III 
group, while the lowest levels were found in the FIGO II and IV groups. Perhaps such 
inconsistent results are due to the limited number of patients studied, but in the literature on the 
subject, similar behaviour of these chemical compounds is pointed out [38]. We believe that 
the analysis of heat shock protein concentrations and the antibodies directed against them in 
women with cervical cancer requires further study. 
We also noted an increase in the concentrations of the tested antibodies with increasing 
depth of endometrial infiltration in women with endometrial cancer. This observation seems to 
be important because the depth of myometrial infiltration may determine the qualification for 
the extension of surgery. The removal of the ovaries may be abandoned in women under the 
age of 45 with radiological or FIGO IA stage endometrial cancer [39–40]. 
We were able to prove the existence of positive correlations between all the tested 
antibodies for those patients with endometrial cancer. This is a consequence of the promotion 
of oncogenesis by multiple types of HSP proteins in cancer cells and the local tumour 
environment in the uterus [41, 42]. Heat shock factor 1 (HSF1) plays a major role here, driving 
the transcription of heat shock proteins and triggering their massive synthesis, enhancing 
oncogenesis [43]. It is also important in cervical cancer patients [44], as confirmed by the 
correlations found in this group as well. It has been shown that in patients with cervical cancer, 
an increase in HSF1 activity is associated with resistance to chemotherapy drugs or a bad 
prognosis [45]. In our study, we were able to obtain an increase in only one of the antibodies 
tested in FIGO stage III, and thus a likely increase in HSF1 in this very group. 
A cardinal challenge in the diagnosis of genital cancers is the discovery of better markers 
to assist in the identification of patients with early-stage cancer. Few biochemical prognostic 
markers are available for the two cancers analysed and none has entered clinical practice 
permanently. To resolve this issue, the biological processes underlying the progression of both 
cancers need to be better understood. The presence of heat shock proteins and anti-HSP 
antibodies in the serum of cancer patients is still an emergent area of research. Although 
autoantibodies to certain HSPs already appear to have relevance as tumour markers in 
osteosarcoma, ovarian cancer, and others, we are now in need of more studies to conclude 




The authors conclude that anti-HSP27 and anti-HSP60 antibodies may therefore be 
biomarkers of carcinogenesis for endometrial and cervical cancer. The concentration of 
antibodies against these proteins may indirectly indicate the cancer stage. The existence of a 
clear positive correlation between the levels of the tested antibodies may indicate a similar 
nature of the participation of HSP27 and HSP60 in the pathogenesis of these tumours. We 
believe that the analysis of heat shock protein concentrations and the antibodies directed against 
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Table 1. Number and percentage of patients with endometrial cancer according to FIGO stage 
of clinical development 
 
Clinical stage of endometrial cancer according to FIGO 
I II III IV 
Group size (n) 21 21 12 5 
Percentage share (%) 35.6 35.6 20.3 8.5 










Clinical stage of cervical cancer according to FIGO 
I II III IV 
Group size (n) 13 17 5 1 
Percentage share (%) 36.1 47.2 13.9 2.8 










Table 2. Concentrations of IgG antibodies against tested heat shock proteins in endometrial 
cancer patients and cervical cancer patients and controls 
Tested parameter 
median, range (AU/mL) 
Endometrial 
cancer 
Cervical cancer Control group 
anti-HSP27 74.3* (9.6–506.3) 58.0* (6.9–914.9) 43.2 (4.8–240.2) 
anti-HSP60 50.2 (2.7–853.7) 43.2 (2.0–494.8) 48.6 (9.4–305.7) 




Table 3. Concentrations of the tested antibodies according to the clinical stage of the neoplastic 
process according to FIGO 
Tested parameter — 
median (AU/mL) 
Clinical stage of endometrial cancer according to FIGO 
classification 
I II III IV 
anti-HSP27 41.2 63.2 76.9 113.4 
anti-HSP60 35.1* 43.8* 52.7 158.5 
Tested parameter — 
median (AU/mL) 
Clinical stage of cervical cancer according to FIGO 
classification 
I II III IV 
anti-HSP27 134.4* 71.9* 56.1 11.1 
anti-HSP60 33.5* 9.2 56.9* 8.5 




Table 4. Levels of tested antibodies according to the depth of endometrial infiltration within 




Clinical stage according to FIGO 
IA IB 
anti-HSP27 33 (11.7–132.8) 46* (19.3–203.8) 
anti-HSP60 28 (8.5–129.4) 41.6* (17.9–199.5) 
* p < 0.05 compared to FIGO IA group 
 
  
Table 5. Evaluation of the correlation between the concentrations of studied antibodies in the 
group of endometrial cancer patients and healthy women  
 anti-HSP27 anti-HSP60 
Endometrial cancer 
anti-HSP27 - 
R = 0.558 
p = 0.000005 
Cervical cancer 
anti-HSP27 - 
R = 0.328 
p = 0.0004 
Healthy women 
anti-HSP27 - 
R = 0.499 
p = 0.00012 
 
p — level and Spearmann's; R — correlation coefficient 
 
